Next Science Ltd Cash Flow Conversion Efficiency
Next Science Ltd cash flow conversion efficiency. Based on the latest financial reports, Next Science Ltd (NXS) has a cash flow conversion efficiency ratio of 2.498x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.39 Million ≈ $-984.59K USD) by net assets (AU$-557.03K ≈ $-394.14K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Next Science Ltd (2016–2024)
Cash flow conversion efficiency of Next Science Ltd from 2016 to 2024. This chart illustrates how Next Science Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Next Science Ltd for real-time trading data and today's change.
Next Science Ltd Cash Flow Conversion Ratio Explained
Next Science Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Next Science Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Next Science Ltd ranked by their cash flow conversion efficiency. Also see Next Science Ltd market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GAMBLING.COM GRP ON
F:6WH
|
0.017x |
|
Columbus Acquisition Corp Unit
NASDAQ:COLAU
|
-0.002x |
|
Atico Mining Corporation
V:ATY
|
0.001x |
|
Daewoo Elec Co
KO:009320
|
0.058x |
|
Yellow Balloon Tour Co. Ltd
KQ:104620
|
-0.237x |
|
Shanghai Lingyun Industries Development Co Ltd
SHG:900957
|
-0.002x |
|
Health In Tech, Inc. Class A Common Stock
NASDAQ:HIT
|
-0.154x |
|
Wattana Karnpaet Public Company Limited
BK:NEW
|
0.042x |
Annual Cash Flow Conversion Efficiency for Next Science Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Next Science Ltd from 2016 to 2024. Review NXS financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$3.44 Million ≈ $2.44 Million |
AU$-7.96 Million ≈ $-5.63 Million |
-2.313x | -96.95% |
| 2023-12-31 | AU$12.82 Million ≈ $9.07 Million |
AU$-15.06 Million ≈ $-10.66 Million |
-1.175x | -18.05% |
| 2022-12-31 | AU$11.85 Million ≈ $8.38 Million |
AU$-11.79 Million ≈ $-8.34 Million |
-0.995x | -29.22% |
| 2021-12-31 | AU$10.73 Million ≈ $7.59 Million |
AU$-8.26 Million ≈ $-5.85 Million |
-0.770x | -21.55% |
| 2020-12-31 | AU$18.80 Million ≈ $13.30 Million |
AU$-11.91 Million ≈ $-8.42 Million |
-0.633x | +1.67% |
| 2019-12-31 | AU$19.37 Million ≈ $13.71 Million |
AU$-12.48 Million ≈ $-8.83 Million |
-0.644x | -31.02% |
| 2018-12-31 | AU$23.74 Million ≈ $16.80 Million |
AU$-11.67 Million ≈ $-8.26 Million |
-0.492x | -1532.03% |
| 2017-12-31 | AU$3.61 Million ≈ $2.55 Million |
AU$-108.77K ≈ $-76.96K |
-0.030x | +98.28% |
| 2016-12-31 | AU$1.34 Million ≈ $948.25K |
AU$-2.35 Million ≈ $-1.66 Million |
-1.751x | -- |
About Next Science Ltd
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more